CLX Investment Company Announces Selection of Contract Research Organization (CRO) for Clinical Trials on Zonda, Inc.'s Rapid Point of Care Test for Chlamydia

MURRIETA, CA--(Marketwire - March 11, 2008) - CLX Investment Company, Inc. (OTCBB: CLXN), which owns 51% of Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for the medical and non-medical markets, today announced that the company has selected Trial Care International, LLC (TCI) to serve as Contract Research Organization (CRO) for the clinical trials for Zonda's rapid point of care test for chlamydia.